Document is current
Any future updates will be listed below
-
Authors
Song, Bing https://orcid.org/0000-0002-9905-410X
Wang, Kaiwen
Na, Saiyang https://orcid.org/0000-0002-2662-5063
Yao, Jia
Fattah, Farjana J.
Martin, Alexandra L.
von Itzstein, Mitchell S.
Yang, Donghan M.
Liu, Jialiang
Xue, Yaming
Liang, Chaoying
Guo, Yuzhi
Raman, Indu
Zhu, Chengsong https://orcid.org/0000-0001-8872-9450
Dowell, Jonathan E.
Homsi, Jade
Rashdan, Sawsan
Yang, Shengjie
Gwin, Mary E.
Wu, Tuoqi https://orcid.org/0000-0002-4003-1034
Hsiehchen, David
Gloria-McCutchen, Yvonne
Lu, Catherine Pei-ju
Raj, Prithvi
Bai, Xiao-chen https://orcid.org/0000-0002-4234-5686
Wang, Jun
Conejo-Garcia, Jose https://orcid.org/0000-0001-6431-4074
Xie, Yang https://orcid.org/0000-0001-9456-1762
Huang, Junzhou https://orcid.org/0000-0002-9548-1227
Gerber, David E. https://orcid.org/0000-0002-7812-6741
Wang, Tao https://orcid.org/0000-0002-4355-149X
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP190208, RP230363, RP230363)
U.S. Department of Health & Human Services | National Institutes of Health (R38HL150214, 1U01AI156189)
American Cancer Society (MRAT-18-114-01-LIB)
V Foundation Robin Roberts Cancer Survivorship
- License Information
-
More Information
Article History
Received: 15 July 2024
Accepted: 19 May 2025
First Online: 27 June 2025
Competing interests
: T.W. reports personal fees from Merck. D.G. has received research funding from Astra-Zeneca, BerGenBio, Karyopharm and Novocure, has stock ownership in Gilead, Medtronic and Walgreens, holds consulting or advisory board positions in Astra-Zeneca, Catalyst Pharmaceuticals, Daiichi-Sankyo, Elevation Oncology, Janssen Scientific Affairs, Jazz Pharmaceuticals, Regeneron Pharmaceuticals and Sanofi and is the cofounder and chief scientific officer of OncoSeer Diagnostics. The remaining authors declare no competing interests.
